MONROVIA, Calif. , Aug. 3, 2016 /PRNewswire/ --  Xencor, Inc.  ( NASDAQ : XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that company management will

-- Expanded bispecific oncology pipeline through strategic collaboration with Novartis and naming of two new drug candidates ---- Xencor management to host conference call today at 4:30 p.m. ET --

MONROVIA, Calif. , July 26, 2016 /PRNewswire/ -- Xencor , Inc. ( NASDAQ : XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release second quarter

- Strategic collaboration announced for bispecific programs: Novartis to receive ex-U.S. rights to XmAb®14045 and XmAb®13676, Xencor to retain U.S. commercial rights -- XmAb®18087 and XmAb®20717 named as two XmAb® bispecific oncology candidates for treatment of neuroendocrine tumors and multiple cancers, respectively; on track to have four bispecific programs in clinic in 2017 -

- Novartis to receive ex-U.S. rights to XmAb14045 and XmAb13676- Xencor retains all U.S. rights to XmAb14045 and XmAb13676- Collaboration also includes XmAb Bispecific Technology for 4 Novartis targets and access to Xencor Fc Technologies

MONROVIA, Calif. , June 14, 2016 /PRNewswire/ --  Xencor, Inc.  ( NASDAQ : XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that the Company will host an

- 75% of high IgE subjects had reduction of free IgE below limit of detection following a single intravenous infusion across all dose levels -- Generally well tolerated as an intravenous infusion with transient, asymptomatic thrombocytopenia at doses ≥2.0 mg/kg -

MONROVIA, Calif. , May 17, 2016 /PRNewswire/ --  Xencor, Inc.  ( NASDAQ : XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat , president

MONROVIA, Calif. , May 2, 2016 /PRNewswire/ --  Xencor, Inc. ( NASDAQ : XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today reported financial results for the first

MONROVIA, Calif. , April 25, 2016 /PRNewswire/ --  Xencor, Inc.  ( NASDAQ : XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release first quarter